XBiotech Inc. heads into today's earnings print with options positioning at its most defensive level in months — a sharp divergence from an otherwise quiet short-selling picture.
The clearest signal is in options. The put/call ratio jumped to 0.76 on May 14, nearly three standard deviations above its 20-day average of 0.39. That is the highest defensive reading since late autumn, and it landed on the session immediately before the earnings release. The spike was abrupt — the PCR had held in a tight range around 0.40 for most of April and early May before doubling in a single day. That kind of sudden move suggests targeted downside hedging, not a gradual shift in sentiment.
Short interest tells a much calmer story. Shares short amount to just 0.54% of the free float — too small to indicate any meaningful bearish conviction from the short-selling community. The week-on-week increase of around 4.6% is a modest uptick in absolute terms, given the tiny base. Borrow costs have actually eased, falling roughly 21% over the past week to 1.33% — a level that signals no squeeze pressure and no rush to establish new short positions. Availability has loosened from the fully-constrained readings seen in late March and early April, when the lending pool was effectively exhausted for several consecutive sessions.
The earnings history adds a note of caution. Of the four most recent events in the data, three produced negative one-day reactions — most sharply a near-11% drop in November 2025, followed by a further decline over the following five days. The two most recent prints, in March 2026, saw smaller initial declines that then reversed into modest five-day gains of 3.5% and 2.1%, respectively. That pattern suggests the stock has been prone to initial selling, with recoveries only emerging later. Stock scores sit in a mid-range at 48 overall, with growth the relative bright spot at a 67th-percentile rank. Concentration in the shareholder register is notable: the top two named holders, Thomas Gut and W. McKenzie, together control over 22% of shares, giving the register an unusually tight-knit character for a micro-cap biotech.
Today's print is less about short-seller conviction — which is almost absent — and more about whether the options market's sudden defensiveness reflects genuine information ahead of results, or simply thin-market hedging in a thinly traded name.
See the live data behind this article on ORTEX.
Open XBIT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
